Search clinical trials for: Bimatoprost and Timolol

Total 270078 results

Laboratoires Thea

Completed

Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.

Ocular Hypertension Glaucoma

Bulgaria
ForSight Vision5, Inc.

Completed

A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

Panama
Aristotle University Of Thessaloniki

Completed

24-hour Intraocular Pressure (IOP) Control With the Bimatoprost/Timolol Fixed Combination (BTFC)

Glaucoma

Greece
Allergan

Completed

Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

China
Larissa University Hospital

Completed

Intraocular Pressure Reduction With the Bimatoprost/Timolol Fixed Combination

Ocular Hypertension | Glaucoma

Greece
Singapore National Eye Centre
Allergan

Unknown

Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study

Glaucoma, Angle-Closure

Singapore
Allergan

Completed

Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Spain, Czech Republic, Germany, Russian Federation, Hungary, Australia, Israel, United Kingdom, United States
Kasr El Aini Hospital

Completed

Bimatoprost/Timolol Versus Travoprost/Timolol

Glaucoma

Egypt
Allergan

Completed

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

United States, Singapore, Italy, United Kingdom, Egypt, Korea, Republic of, Argentina, Canada, Colombia, Czechia, Germany, Malaysia, New Zealand, South Africa, Turkey
Allergan

Completed

Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients Wtih Glaucoma or Ocular Hypertension

Ocular Hypertension

United States
Allergan

Completed

Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension

Germany, Canada, United States, Austria
Allergan

Completed

Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension

United States, Canada
Allergan

Completed

Safety and Efficacy of Bimatoprost/Timolol (Ganfort®) Ophthalmic Solution in Korea

Ocular Hypertension | Glaucoma, Open-Angle

Korea, Republic of
Allergan

Completed

Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

United States, Hong Kong, Taiwan, Spain, Israel, Australia, Austria, Belgium, Brazil, Denmark, Hungary, Peru, Philippines, Poland
Allergan

Terminated

A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma

Glaucoma

United Kingdom, Taiwan, Korea, Republic of, United States, Italy, Philippines, France
Allergan

Completed

Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Canada
Allergan

Completed

A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting

Ocular Hypertension | Glaucoma, Primary Open Angle

Germany
Allergan

Completed

GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy

Ocular Hypertension | Glaucoma, Open-Angle

Austria
Allergan

Completed

Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

China
Innovative Medical

Completed

Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension

Glaucoma

United States
Afyon Kocatepe University Hospital

Completed

Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma

Glaucoma, Open-Angle
Santen Pharmaceutical (Taiwan) Co., LTD

Completed

Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting

Primary Open Angle Glaucoma | Ocular Surface Disease

Taiwan
SpyGlass Pharma, Inc.

Recruiting

Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution (Tigris)

Ocular Hypertension | Glaucoma | Cataract

United States
Pharmaceutical Research Network

Completed

Lumigan Versus Cosopt

Open-Angle Glaucoma

United States
University of Campinas, Brazil

Completed

Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG

Uveitis, Anterior | Cystoid Macular Edema

Brazil
University of Parma

Completed

24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension

Ocular Hypertension

Italy
Allergan

Completed

Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated

Glaucoma, Open-Angle

Spain, Portugal
Allergan

Completed

Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Brazil
Allergan

Completed

Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Mexico, Colombia
Allergan

Completed

Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

India
CT Glaucoma Associates

Recruiting

How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?

Glaucoma, Open-Angle | Glaucoma; Drugs

United States
Allergan

Completed

Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

Alopecia | Alopecia, Androgenetic | Baldness

United States
Allergan

Completed

A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

Alopecia | Alopecia, Androgenetic | Baldness

United States
University of Milan

Completed

Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on 24-hour Blood and Ocular Perfusion Pressures

Glaucoma

Germany, Greece, Italy, Switzerland, United Kingdom
Allergan

Completed

Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)

Glaucoma, Open-Angle | Normal Tension Glaucoma

Korea, Republic of
Allergan

Completed

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States, Israel, Canada, Singapore, Philippines, Spain, Australia, Belgium, Brazil, Germany
Allergan

Completed

Bimatoprost in the Treatment of Eyelash Hypotrichosis

Idiopathic Eyelash Hypotrichosis

Russian Federation, Sweden, United States, United Kingdom
Allergan

Completed

Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

United States
Allergan

Completed

Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction

Ocular Hypertension | Glaucoma, Open-Angle

Canada
AbbVie

Active, not recruiting

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States, Argentina, Australia, Bulgaria, Czechia, Denmark, Germany, Hungary, Ireland, Italy, New Zealand, Poland, Russian Federation, South Africa, Sweden, United Kingdom
Kenneth Beer
Allergan

Completed

Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo

Hypotrichosis

United States
Allergan

Completed

Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia

Androgenetic Alopecia

United States
Allergan

Completed

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Bimatoprost for the Treatment of Eyebrow Hypotrichosis

Eyebrow Hypotrichosis

United States, Canada
Aristotle University Of Thessaloniki

Completed

24-Hour Intraocular Pressure Control With Bimatoprost/Timolol Versus Latanoprost as First Choice

Glaucoma

Greece
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis

Eyelash Hypotrichosis

Japan
AbbVie

Completed

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss

Alopecia | Baldness

United States, Germany
Allergan

Completed

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States

3

Subscribe